Related Experiment Video
Updated: Feb 19, 2026
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
Peter Valent1,2, Attilio Orazi3, David P Steensma4
1Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Abstract:
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between ´normal´, pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice.
Insights
Myelodysplastic syndromes (MDS) are myeloid neoplasms with evolving diagnostic challenges. This consensus proposes new criteria to classify pre-MDS conditions and refine MDS diagnosis for better patient outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Diagnostics
Background:
- Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms with a significant risk of transforming into acute myeloid leukemia (AML).
- Recent advances in molecular markers and targeted therapies have introduced complexities in MDS diagnosis and prognostication.
- Pre-MDS conditions, characterized by cytopenia and molecular lesions, pose diagnostic challenges due to their potential to evolve into MDS or other neoplasms.
Purpose of the Study:
- To address the challenges in diagnosing and classifying pre-MDS conditions and MDS.
- To propose updated minimal diagnostic criteria for MDS and standards for differentiating normal, pre-MDS, and MDS states.
- To facilitate improved diagnostic and prognostic evaluations in clinical research and practice.
Main Methods:
- Convened an international consensus conference in July 2016 to discuss diagnostic and classification issues in MDS.
- Reviewed recent molecular, cytogenetic, and flow-based parameters relevant to MDS and pre-MDS conditions.
- Developed proposed criteria for classifying pre-MDS conditions and updated minimal diagnostic criteria for MDS.
Main Results:
- Summarized outcomes of the international consensus conference on MDS and pre-MDS.
- Presented proposed criteria for the classification of pre-MDS conditions.
- Offered updated minimal diagnostic criteria for MDS and proposed standards for delineating normal, pre-MDS, and MDS.
Conclusions:
- The proposed classification and diagnostic standards aim to clarify the continuum from normal hematopoiesis to MDS.
- Implementation of these criteria is expected to enhance diagnostic accuracy and prognostic evaluation in MDS.
- This work provides a framework for future research and clinical management of patients with MDS and related conditions.
